CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Inc.

1:19-cv-01489

📡 5G SEP • ETSI Declared

Overview

Case Number 1:19-cv-01489
Filing Date 2019-08-09
Status Terminated
Termination Date 2021-08-30
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Plaintiff

Merck Sharp & Dohme Corp. Operating Company

Represented By

17 Attorneys Listed

Vanessa O. Omoroghomwan

Email: vomoroghomwan@wc.com

Jeffrey G. Ho

UNDELIVERABLE EMAIL 9/20/2021

Sarahi Uribe

Email: suribe@wc.com

Elise M. Baumgarten

Email: ebaumgarten@wc.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Alexandra M. Joyce

McCarter & English, LLP

Tel: +1 (302) 984-6392
Fax: +1 (302) 450-4235

Renaissance Centre, 405 N. King Street, 8th Floor

Stanley E. Fisher

Williams & Connolly LLP - Washington

Tel: +1 (202) 434-5000

725 Twelfth St, NW, Washington, DC 20005

Shaun P. Mahaffy

Williams & Connolly LLP - Washington

Tel: +1 (202) 434-5000
Fax: +1 (202) 434-5029

725 Twelfth St, NW, Washington, DC 20005

Sandra K. Law

Schrader, Byrd & Companion, PLLC - Wheeling

Tel: +1 (304) 233-3390
Fax: +1 (304) 233-2769

The Maxwell Centre, Suite 500, 32 - 20th Street

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Jingyuan Luo

Williams & Connolly LLP - Washington

Tel: +1 (202) 434-5000
Fax: +1 (202) 434-5029

725 Twelfth St, NW, Washington, DC 20005

Jessamyn S. Berniker

Williams & Connolly LLP - Washington

Tel: +1 (202) 434-5000
Fax: +1 (202) 434-5029

725 Twelfth St, NW, Washington, DC 20005

James F. Companion

Schrader Companion Duff & Law, PLLC

Tel: +1 (304) 233-3390
Fax: +1 (304) 233-2769

401 Main Street, Wheeling, WV 26003

Frank X. Duff

Schrader, Byrd & Companion, PLLC - Wheeling

Tel: +1 (304) 233-3390
Fax: +1 (304) 233-2769

The Maxwell Centre, Suite 500, 32 - 20th Street

Bruce R. Genderson

Email: bgenderson@wc.com

Anthony Sheh

Williams & Connolly LLP - Washington

Tel: +1 (202) 434-5000
Fax: +1 (202) 434-5029

725 Twelfth St, NW, Washington, DC 20005

Alexander S. Zolan

Williams & Connolly LLP - Washington

Tel: +1 (202) 434-5000
Fax: +1 (202) 434-5029

725 Twelfth St, NW, Washington, DC 20005

Counter Claimant

Mylan Pharmaceuticals Inc. Operating Company

Represented By

9 Attorneys Listed

Lance A. Soderstrom

Email: lance.soderstrom@katten.com

Kenneth Laurence Dorsney

Morris James LLP

Tel: +1 (302) 888-6855
Fax: +1 (302) 571-1750

500 Delaware Avenue, Suite 1500

Matthew M. Holub

Email: matthew.holub@kattenlaw.com

William J O'Brien

Steptoe & Johnson PLLC - Bridgeport

Tel: +1 (304) 933-8181
Fax: +1 (304) 933-8183

400 White Oaks Blvd, Bridgeport, WV 26330

Joseph M. Janusz

Email: joe.janusz@kattenlaw.com

Jitendra Malik

Katten Muchin Rosenman LLP - NC

Tel: +1 (704) 344-3185
Fax: +1 (704) 444-2050

550 S. Tyron Street, Suite 2900

Deepro R. Mukerjee

Katten Muchin Rosenman LLP

Tel: +1 (212) 940-8552
Fax: +1 (312) 222-6345

575 Madison Avenue, New York, NY 10022

Alissa M. Pacchioli

Katten Muchin Rosenman LLP - NC

Tel: +1 (704) 444-2000

550 S. Tyron Street, Suite 2900

Gordon H. Copland

Steptoe & Johnson PLLC - Bridgeport

Tel: +1 (304) 933-8162
Fax: +1 (304) 933-8183

400 White Oaks Blvd, Bridgeport, WV 26330

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 2 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 5 proceedings
🏛️
USPTO PTAB Trials 4 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (2): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (9 found):
PTAB: 4 U.S. Courts: 5
USPTO PTAB Trial 2020-06-12
IPR2020-01072

Sun Pharmaceutical Industries Ltd. et al. v. Merck Sharp & Dohme Corp. et al.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2020-06-11
IPR2020-01060

Dr. Reddy's Laboratories, Inc. et al. v. Merck Sharp & Dohme Corp. et al.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2020-06-10
IPR2020-01045

Teva Pharmaceuticals USA, Inc. v. Merck Sharp & Dohme Corp.

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2019-10-30
IPR2020-00040

Mylan Pharmaceuticals, Inc. v. Merck Sharp & Dohme Corp. et al.

Asserted Patent
Status: Final Written Decision
U.S. District Court 2019-02-13
1:19-cv-00312

Merck Sharp & Dohme Corp. v. Sandoz Inc.

Asserted Patent
Status: DED
U.S. District Court 2019-02-13
1:19-cv-00318

Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc.

Asserted Patent
Status: DED
U.S. District Court 2019-02-13
1:19-cv-00319

Merck Sharp & Dohme Corp. v. Sun Pharmaceutical Industries Ltd.

Asserted Patent
Status: DED
U.S. District Court 2019-02-13
1:19-cv-00310

Merck Sharp & Dohme Corp. v. Alvogen Pine Brook LLC

Asserted Patent
Status: DED
U.S. District Court 2019-02-13
1:19-cv-00317

Merck Sharp & Dohme Corp. v. Watson Laboratories, Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP • ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 4G / 5G LTE Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Sharp

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.

✓ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
✓ Right to demand global FRAND portfolio determination.
✓ Non-discrimination defense: check licensing terms offered to competing implementers.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7326708
Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Filed: 2004-06-23
Issued: 2008-02-05
Expiring Soon (4 days) +884d PTA
Expires: 2026-11-24
US8414921
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Filed: 2006-12-12
Issued: 2013-04-09
Active (1.7 yrs remaining) +587d PTA
Expires: 2028-07-21

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Narrowing Window — Less than 6 months of enforceable term remains. Courts rarely grant preliminary or permanent injunctions when term expiration is imminent.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+884 days) / Cellect Scrutiny — Over 884 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

49

Dispositive

8

Granted

17

Denied

1

Pending / Review

24

Motions by Category

Procedural / Extension Motion 27 Motion to Transfer Venue (28 U.S.C. § 1404) 1 Motion to Dismiss (FRCP 12(b)(6)) 3 Motion to Dismiss 4 Claim Construction / Markman Filing 14

Key Dispositive Motions & Rulings

Motion to Dismiss Denied
ORDER DENYING AS MOOT THE DEFENDANTS' PARTIAL MOTION TO DISMISS (DKT. NO. 30 ). Signed by Senior Judge Irene M. Keeley on 7/18/2019. (dk) [Transferred from West...
Entry #44 • 2019-07-18 Document →
Motion to Dismiss (FRCP 12(b)(6)) Granted
ORDER granting 40 Stipulation Extending Plaintiff's Time to Respond to 30 MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM AND FOR LACK OF SUBJECT-MATTER JURISDIC...
Entry #41 • 2019-06-28 Document →
Motion to Dismiss Granted
STIPULATION Extending Plaintiff's Time to Respond to Motion to Dismiss by Merck Sharp & Dohme Corp.. (Companion, James) [Transferred from West Virginia Northern...
Entry #40 • 2019-06-27 Document →
Motion to Dismiss Pending / Under Review
STIPULATION Extending Plaintiff's Time to Respond to Motion to Dismiss by Merck Sharp & Dohme Corp.. (Companion, James) [Transferred from West Virginia Northern...
Entry #35 • 2019-06-07 Document →
Motion to Dismiss (FRCP 12(b)(6)) Pending / Under Review
STIPULATION EXTENDING PLAINITFF'S TIME TO RESPOND TO MOTION TO DISMISS as to 30 MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM AND FOR LACK OF SUBJECT-MATTER JU...
Entry #36 • 2019-06-07 Document →
Motion to Dismiss (FRCP 12(b)(6)) Pending / Under Review
MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM AND FOR LACK OF SUBJECT-MATTER JURISDICTION by Mylan Inc., Mylan Pharmaceuticals Inc.. (Copland, Gordon) [Transfe...
Entry #30 • 2019-05-31 Document →

Docket Entries

(280 total)
Pleading / Complaint

COMPLAINT against Mylan Inc., Mylan Pharmaceuticals Inc., filed by Merck Sharp & Dohme Corp. (Attachments: # 1 Exhibit A - Patent Information, # 2 Exhibit B - Patent Information, # 3 Civil Cover Sheet)(mh) [Transferred from West Virginia Northern on 8/9/2019.] (Entered: 05/02/2019)

Entry #1 • 2019-05-02
1

Corporate Disclosure Statement by Merck Sharp & Dohme Corp. identifying Corporate Parent Merck & Co., Inc. for Merck Sharp & Dohme Corp. (mh) [Transferred from West Virginia Northern on 8/9/2019.] (Entered: 05/02/2019)

Entry #2 • 2019-05-02
1
Pleading / Complaint

Supplemental Information for Patent Cases Involving an Abbreviated New Drug Application (ANDA) re 1 Complaint filed by Merck Sharp & Dohme Corp. (mh) [Transferred from West Virginia Northern on 8/9/2019.] (Entered: 05/02/2019)

Entry #3 • 2019-05-02
1

Filing fee: $ 400.00, receipt number WVNW002169 (mh) [Transferred from West Virginia Northern on 8/9/2019.] (Entered: 05/02/2019)

Entry #4 • 2019-05-02
1
Pleading / Complaint

REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (mh) [Transferred from West Virginia Northern on 8/9/2019.] (Entered: 05/02/2019)

Entry #5 • 2019-05-02
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc